Advertisement

Topics

Companies Related to "Resistance to Aspirin and/or Clopidogrel Among Patients With PAD." [Most Relevant Company Matches] RSS

00:51 EST 22nd February 2019 | BioPortfolio

Here are the most relevant search results for "Resistance to Aspirin and/or Clopidogrel Among Patients With PAD." found in our extensive corporate database of over 50,000 company records.

Showing "Resistance Aspirin Clopidogrel Among Patients With" Companies 1–25 of 3,900+

Relevant

Virco Lab, Inc.

Virco BVBA is a world leader in the field of HIV resistance testing services for clinical practice and clinical studies, advancing research that correlates laboratory testing with clinical management, while offering a wide range of HIV resistance diagnostics. (Virco Lab, Inc. is the US operating division of Virco.) The company applies the latest technologies in molecular biology, medical virology,...


Paratek Pharmaceuticals Incorporated

Paratek's mission is to overcome the major worldwide problem of bacterial resistance through the application of new proprietary technology and through the development of new antibiotics. Paratek has established two product development programs to identify and develop new pharmaceuticals for the treatment of infectious diseases:The Tetracycline Resistance Project ("Tet Project") based on expertise ...

Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for


Allecra Therapeutics GmbH

Allecra Therapeutics Allecra is a biopharmaceutical company established in 2013 focussed on the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra’s Mission Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving ...

Mpex Pharmaceuticals, Inc.

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacte...

Teva Pharmaceutical Industries Ltd. & OncoGenex Pharmaceuticals, Inc.

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the le...

Checkmate Pharmaceuticals Inc.

Checkmate Pharmaceuticals is a clinical stage company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate’s lead product candidate, CMP-001, ...

Deciphera Pharmaceuticals, Inc.,

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

VIRalliance

VIRalliance develops and markets high added value services and products to help optimise drug discovery and patient treatment in the fields of infectious diseases and oncology.VIRalliance has a development portfolio of innovative predictive tests to aid the optimal treatment.PHENOSCRIPT™ is the first of these tests to be made available to the public. PHENOSCRIPT™ is a novel and rapid HIV phen...

The Medicines Company

The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon ang...

Medicines Co.

The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon ang...

Accumetrics

Accumetrics develops, manufactures, and markets the VerifyNow™ System, a comprehensive system for the assessment of platelet function. Modulation of platelet function plays a critical role in effectively treating cardiovascular, cerebrovascular, and peripheral vascular disease. VerifyNow is the only rapid platelet function test shown to correlate with clinical outcomes. The tests provide doctors...

Mobidiag Ltd.

Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag...

Pharmaceutica Limited

Pharmaceutica Limited is a privately owned pharmaceutical company founded in March 2003, to discover and develop a new generation of anti-infective drug technologies that combat the increasing problem caused by the rapid evolution of resistance by pathogenic organisms. The company is targeting both human and veterinary applications for its technologies.The initial focus is to find a solution to th...

Probably Relevant

AB BIODISK

The AB BIODISK name, company spirit and reputation are based on commitment to the highest standards of science. The company is perhaps best known for its dedication to antimicrobial resistance testing since the early 1950s. The mission left by its scientific founder, Hans Ericsson, Professor of Microbiology at the Karolinska Institute, “to Promote the Rational Use of Antibiotics” has been fait...

BioAlliance Pharma

BioAlliance Pharma (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections.To attack the challenge of resistance, the company has multiple product opportunities in two broad proprietary drug delivery systems represented by the Lauriad® adhesive tech...

UTILITY therapeutics Limited

UTILITY therapeutics is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development...

Discuva

Discuva aims to revolutionise the treatment of disease caused by bacterial infection by discovering and developing new antibiotics against highly drug-resistant pathogens. The company’s innovative proprietary technologies both identify new small molecule drugs against novel bacterial targets and facilitate their progression through to drug candidates ...

PLx Pharma

PLx Pharma is a privately-owned pharmaceutical company developing proprietary formulations of proven nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, naproxen and ibuprofen which possess significantly improved gastrointestinal (GI) safety profiles. Based on PLx’s unique phospholipid based drug delivery technology, these products are desi...

UTILITY therapeutics Ltd

UTILITY is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development today.

Debiopharm Group

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect on HCV replication both in vitro and in vivo. Debio 025 has excellent antiviral activity against a broad range of genotypes (1, 2, 3 and 4); a high barrier to the development of resistance; and the pos...

ConjuGon

The rise of drug-resistant strains of pathogenic bacteria is quickly becoming a health problem of potentially crisis proportions. Virtually all experts agree that entirely new approaches are needed to go beyond the use of traditional antibiotics. Fundamentally new, even radical, anti-microbial agents are necessary to kill pathogenic bacteria while minimizing the ability of the bacteria to develop ...

Corgenix Medical Corp.

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently ...

NewBiotics

NewBiotics Inc. is a pharmaceutical developer of breakthrough drugs to treat cancer and infectious disease. The privately held company is applying its Enzyme Catalyzed Therapeutic Activation (ECTA) technology to develop a new generation of pharmaceuticals that transform drug resis-tance into therapeutic advantage. Unlike conventional agents that kill diseased cells by enzyme inhibition – with to...


More From BioPortfolio on "Resistance to Aspirin and/or Clopidogrel Among Patients With PAD."

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks